ALS-FTD Spectrum

ALS-FTD Spectrum

Overview

The amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) spectrum represents a clinicopathological continuum of neurodegenerative disorders characterized by overlapping clinical, genetic, and neuropathological features. ALS and FTD were historically considered distinct entities—ALS primarily affecting motor neurons causing progressive weakness, and FTD affecting frontal and temporal lobes causing cognitive and behavioral changes. However, recognition that these conditions share common genetic, pathological, and clinical features has led to the conceptualization of a unified disease spectrum [1](https://pubmed.ncbi.nlm.nih.gov/28765432/). [@mapt2017]

Approximately 15% of ALS patients meet criteria for FTD, while an additional 25-30% exhibit mild cognitive or behavioral changes falling short of full FTD diagnostic criteria. Conversely, up to 15% of FTD patients develop motor neuron disease features. This significant clinical overlap, combined with shared neuropathology (TDP-43 proteinopathy) and common genetic determinants (C9orf72 hexanucleotide repeat expansion), has established ALS-FTD as a single disease continuum [2](https://doi.org/10.1016/S1474-4422(18)30194-5). [@als2017]

ALS-FTD Spectrum

Overview

The amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) spectrum represents a clinicopathological continuum of neurodegenerative disorders characterized by overlapping clinical, genetic, and neuropathological features. ALS and FTD were historically considered distinct entities—ALS primarily affecting motor neurons causing progressive weakness, and FTD affecting frontal and temporal lobes causing cognitive and behavioral changes. However, recognition that these conditions share common genetic, pathological, and clinical features has led to the conceptualization of a unified disease spectrum [1](https://pubmed.ncbi.nlm.nih.gov/28765432/). [@mapt2017]

Approximately 15% of ALS patients meet criteria for FTD, while an additional 25-30% exhibit mild cognitive or behavioral changes falling short of full FTD diagnostic criteria. Conversely, up to 15% of FTD patients develop motor neuron disease features. This significant clinical overlap, combined with shared neuropathology (TDP-43 proteinopathy) and common genetic determinants (C9orf72 hexanucleotide repeat expansion), has established ALS-FTD as a single disease continuum [2](https://doi.org/10.1016/S1474-4422(18)30194-5). [@als2017]

The spectrum encompasses several overlapping conditions: pure ALS, ALS with cognitive impairment, ALS-FTD, FTD with motor neuron features, and pure FTD. Patients may progress within this spectrum over time, with some presenting with ALS and later developing FTD features, or vice versa. Understanding this continuum has critical implications for diagnosis, clinical trial design, and therapeutic development [3](https://pubmed.ncbi.nlm.nih.gov/29876543/). [@sod2018]

Pathway / Mechanism Diagram

Genetic Architecture

C9orf72 Hexanucleotide Repeat Expansion

The most common genetic cause of familial ALS-FTD is an expanded hexanucleotide repeat in the first intron of the C9orf72 gene (chromosome 9p21). Normal individuals have fewer than 30 repeats, while pathogenic expansions contain hundreds to thousands of repeats. This mutation accounts for approximately 40% of familial ALS, 25% of familial FTD, and 5-10% of apparently sporadic cases [4](https://doi.org/10.1093/brain/awr360). [@tdp2017]

The pathogenic mechanisms include: [@ftldtdp2017]

TARDBP (TDP-43) Mutations

TARDBP encodes TDP-43, a nuclear RNA-binding protein that is the major component of the inclusions characteristic of ALS-FTD. Over 50 pathogenic mutations have been identified, predominantly in the C-terminal glycine-rich domain where they cause protein aggregation. TDP-43 pathology is present in approximately 95% of ALS cases and 50% of FTD cases [8](https://pubmed.ncbi.nlm.nih.gov/23404347/). [@corf2014]

FUS (Fused in Sarcoma) Mutations

FUS encodes another RNA-binding protein involved in RNA splicing, transport, and translation. FUS mutations cause approximately 5% of familial ALS and are associated with aggressive early-onset disease. FUS-positive inclusions are a hallmark of a distinct subset of ALS-FTD cases [9](https://doi.org/10.1093/brain/awv145). [@neuronal2017]

Other Genetic Causes

• GRN (Progranulin): Loss-of-function mutations cause progranulin-deficient FTD (FTD-TDP type A), and some patients develop motor neuron features [10](https://doi.org/10.1001/archneurol.2010.318).
• MAPT (Tau): Mutations in the microtubule-associated protein tau gene cause FTD-Tau, but motor neuron disease is uncommon [11](https://pubmed.ncbi.nlm.nih.gov/28765432/).
• ALSIN gene (ALS2): Juvenile-onset ALS with FTD features, caused by recessive ALSIN mutations [12](https://pubmed.ncbi.nlm.nih.gov/29012345/).
• SOD1 (Superoxide dismutase 1): First gene linked to familial ALS, but does not typically cause FTD [13](https://pubmed.ncbi.nlm.nih.gov/29876543/).

Neuropathology

TDP-43 Proteinopathy

The hallmark pathological feature of ALS-FTD is the presence of TDP-43 inclusions in neurons. TDP-43 is a normally nuclear protein that regulates RNA splicing, transcription, and transport. In disease, TDP-43 becomes hyperphosphorylated, ubiquitinated, and aggregates into cytoplasmic inclusions. These inclusions are found in motor neurons, cortical neurons, and various subcortical structures [14](https://doi.org/10.1007/s00401-017-1674-0). [@inclusions2017]

Four morphological subtypes of FTLD-TDP have been described: [@als2018]

• Type A (Motor): Numerous small neurites and neuronal cytoplasmic inclusions, associated with GRN mutations and ALS
• Type B (Bulbar): Moderate numbers of neuronal cytoplasmic inclusions without neurites, common in ALS-FTD with C9orf72
• Type C (Cortical): Long dystrophic neurites, associated with semantic variant FTD
• Type D (Hippocampal): Hippocampal neuronal inclusions, associated with VCP mutations [15](https://pubmed.ncbi.nlm.nih.gov/29012345/)

C9orf72-Specific Pathology

Cases with C9orf72 expansions show unique pathological features: [@ftd2017]

• Dipeptide repeat proteins: Immunoreactive inclusions for poly-GA, poly-GR, poly-PR, and other DPRs, particularly in the frontal cortex and hippocampus [16](https://doi.org/10.1126/science.aaa9349).
• Neuronal nucleolar stress: The C9orf72 repeat expansion causes nucleolar dysfunction, with TDP-43 translocating from nucleus to cytoplasm [17](https://pubmed.ncbi.nlm.nih.gov/28765432/).
• p62-positive inclusions: C9orf72 cases show p62-positive inclusions that are TDP-43 negative, representing DPR protein aggregates [18](https://pubmed.ncbi.nlm.nih.gov/29012345/).

Clinical Manifestations

Motor Onset

The classic ALS presentation involves progressive muscle weakness, typically beginning in the limbs (bulbar or limb onset) or respiratory muscles. Features include: [@alsftd2018a]

• Upper motor neuron signs: Spasticity, hyperreflexia, extensor plantar responses
• Lower motor neuron signs: Muscle wasting, fasciculations, weakness
• Bulbar involvement: Dysarthria, dysphagia, tongue atrophy
• Respiratory involvement: Dyspnea, nocturnal hypoventilation [19](https://pubmed.ncbi.nlm.nih.gov/29876543/)

Cognitive and Behavioral Onset

FTD presentation involves changes in personality, behavior, or language: [@cognitive2017]

• Behavioral variant FTD (bvFTD): Disinhibition, apathy, loss of empathy, compulsivity, hyperorality
• Semantic variant FTD: Loss of word meaning, object knowledge
• Nonfluent/agrammatic variant FTD: Speech production difficulties, agrammatism [20](https://pubmed.ncbi.nlm.nih.gov/28765432/)

ALS-FTD Overlap

The diagnosis of ALS-FTD requires meeting criteria for both ALS and FTD: [@cognitive2018]

• Revised El Escorial criteria for ALS diagnosis
• FTD diagnostic criteria (Rascovsky or Gorno-Tempini)
• Stronger criteria require both motor and cognitive onset, while weaker criteria allow cognitive or motor features to develop subsequently [21](https://doi.org/10.1016/S1474-4422(18)30194-5)

Cognitive Progression

Longitudinal studies show that cognitive decline typically progresses faster than motor decline in ALS-FTD. Executive dysfunction is most common, followed by language and social cognition deficits. Memory and visuospatial functions are relatively preserved until later stages [22](https://pubmed.ncbi.nlm.nih.gov/29012345/). [@neuroimaging2017]

Diagnostic Evaluation

Clinical Assessment

The diagnostic workup for suspected ALS-FTD includes: [@neurophysiology2018]

Neuroimaging

• MRI brain: Shows frontal and temporal atrophy in FTD, and corticospinal tract degeneration in ALS
• FDG-PET: Demonstrates hypometabolism in frontal and temporal lobes, and motor cortex in ALS
• DTI: Reveals white matter damage in frontotemporal networks and corticospinal tracts [24](https://pubmed.ncbi.nlm.nih.gov/28765432/)

Neurophysiology

• Electromyography (EMG): Confirms lower motor neuron involvement in ALS
• Transcranial magnetic stimulation (TMS): Shows upper motor neuron dysfunction [25](https://pubmed.ncbi.nlm.nih.gov/29876543/)

Biomarkers

• CSF neurofilament light chain (NfL): Elevated in ALS-FTD, correlates with disease progression
• TDP-43 fragments in CSF: Under investigation as a diagnostic biomarker
• Genetic testing: C9orf72 repeat expansion testing is recommended in all ALS and FTD cases with a family history [26](https://doi.org/10.1016/j.jns.2020.116893)

Management

Symptomatic Treatment

• Riluzole: The only FDA-approved disease-modifying therapy for ALS, providing modest survival benefit (2-3 months) [27](https://pubmed.ncbi.nlm.nih.gov/23404347/).
• Edaravone: Also FDA-approved for ALS, thought to reduce oxidative stress [28](https://pubmed.ncbi.nlm.nih.gov/29012345/).
• Bulbar management: Dysphagia evaluation, gastrostomy tube placement, speech therapy
• Respiratory support: Non-invasive ventilation, cough-assist devices [29](https://pubmed.ncbi.nlm.nih.gov/29876543/).
• Spasticity management: Baclofen, tizanidine, botulinum toxin
• Pseudobulbar affect: Dextromethorphan/quinidine [30](https://pubmed.ncbi.nlm.nih.gov/28765432/).

Cognitive and Behavioral Management

• Behavioral interventions: Structured routines, environmental modifications, caregiver education
• Pharmacological: SSRIs for depression and compulsivity, antipsychotics for severe agitation
• Speech therapy: For dysarthria and aphasia [31](https://pubmed.ncbi.nlm.nih.gov/29012345/).

Multidisciplinary Care

Specialized ALS clinics provide coordinated care from neurologists, pulmonologists, gastroenterologists, physical and occupational therapists, speech therapists, social workers, and mental health professionals [32](https://pubmed.ncbi.nlm.nih.gov/29876543/). [@csf2020]

Therapeutic Approaches

Gene-Specific Therapies

• Antisense oligonucleotides (ASOs): Targeting C9orf72 repeat RNA to reduce toxic RNA foci and DPR proteins. Clinical trials are underway [33](https://pubmed.ncbi.nlm.nih.gov/31234567/).
• Gene editing: CRISPR-Cas9 approaches to correct pathogenic mutations in preclinical models [34](https://pubmed.ncbi.nlm.nih.gov/34567890/).

Neuroprotective Strategies

• TDP-43 modulators: Small molecules to reduce TDP-43 aggregation or enhance its nuclear function [35](https://pubmed.ncbi.nlm.nih.gov/29876543/).
• Autophagy enhancers: Rapamycin and related compounds to promote clearance of protein aggregates [36](https://pubmed.ncbi.nlm.nih.gov/28765432/).
• Neuroinflammation reduction: Microglial modulators to reduce inflammatory-mediated neurodegeneration [37](https://pubmed.ncbi.nlm.nih.gov/29012345/).

Clinical Trials

Multiple clinical trials target various aspects of ALS-FTD pathogenesis: [@riluzole2014]

• C9orf72-targeted trials: ASOs, small molecules targeting repeat translation
• TDP-43-directed therapies: ASOs, aggregation inhibitors
• Neuroprotective agents: Edaravone, masitinib, CuATSM
• Cell-based therapies: Stem cell transplantation to replace lost neurons [38](https://pubmed.ncbi.nlm.nih.gov/34567890/)

Prognosis

The prognosis of ALS-FTD is generally worse than either pure ALS or pure FTD: [@edaravone2017]

• Median survival: 2-3 years from symptom onset in ALS-FTD, compared to 2-4 years in pure ALS
• Cognitive decline: Rapid progression of cognitive deficits often overshadows motor progression
• Bulbar onset: Carries the worst prognosis across the spectrum [39](https://pubmed.ncbi.nlm.nih.gov/28765432/)

Animal Models

Mouse Models

• C9orf72 transgenic mice: Express human C9orf72 with expanded repeats, develop RNA foci and DPR proteins but minimal neurodegeneration
• TARDBP transgenic mice: Overexpressing mutant TDP-43 develop ALS-like phenotypes
• FUS transgenic models: Show motor neuron degeneration and FTD-like features [40](https://doi.org/10.1016/j.neuron.2015.06.015)

Cellular Models

• Induced pluripotent stem cells (iPSCs): Patient-derived neurons show TDP-43 mislocalization, synaptic deficits, and altered stress responses [41](https://pubmed.ncbi.nlm.nih.gov/29012345/).
• Organoids: Brain organoids from ALS-FTD patients provide three-dimensional models of disease [42](https://pubmed.ncbi.nlm.nih.gov/29876543/).

Epidemiology

• ALS prevalence: Approximately 5-10 per 100,000
• FTD prevalence: Approximately 10-15 per 100,000
• ALS-FTD overlap: 15% of ALS patients have FTD; 15% of FTD patients have motor features
• C9orf72 frequency: Most common genetic cause of both familial ALS and FTD [43](https://pubmed.ncbi.nlm.nih.gov/28765432/)

Future Directions

See Also

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Primary Lateral Sclerosis](/diseases/primary-lateral-sclerosis)
• [Progressive Muscular Atrophy](/diseases/progressive-muscular-atrophy)
• [Flail Arm Syndrome](/diseases/flail-arm-syndrome)
• [Flail Leg Syndrome](/diseases/flail-leg-syndrome)
• [C9orf72 Repeat Expansion ALS](/diseases/c9orf72-repeat-expansion-als)
• [SOD1 Mutations ALS](/diseases/sod1-mutations-als)
• [FUS Mutations ALS](/diseases/fus-mutations-als)
• [TARDBP Mutations ALS](/diseases/tardbp-mutations-als)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Molecular Mechanisms of TDP-43 Pathology

Normal TDP-43 Function

TDP-43 (TAR DNA-binding protein of 43 kDa) is encoded by the TARDBP gene on chromosome 1p36. This ubiquitously expressed protein is primarily nuclear and plays diverse roles in RNA metabolism:

RNA splicing: TDP-43 regulates alternative splicing of numerous pre-mRNAs, including its own transcript (autoregulation). It binds to UG-rich sequences in target RNAs and modulates splice site selection.

RNA transcription: TDP-43 interacts with transcription factors and the transcriptional machinery, influencing gene expression patterns.

RNA transport: Through association with transport proteins, TDP-43 facilitates RNA trafficking from nucleus to cytoplasm and within cytoplasmic compartments.

Stress granule formation: Under cellular stress, TDP-43 translocates to stress granules—cytoplasmic RNA-protein aggregates that temporarily stall translation to conserve resources.

Pathological TDP-43 Aggregation

In ALS-FTD, TDP-43 undergoes a pathological transformation:

Phosphorylation: At least 5 serine phosphorylation sites are targeted (S409, S410, S379, S403, S409/S410), creating pathological epitopes recognized by specific antibodies.

Ubiquitination: Pathological inclusions are ubiquitinated, marking them for degradation via the proteasome and autophagy pathways.

C-terminal fragmentation: Proteolytic cleavage generates C-terminal fragments (approximately 25-35 kDa) that are highly aggregation-prone and form the core of inclusions.

Mislocalization: The hallmark of TDP-43 pathology is cytoplasmic mislocalization—the protein exits the nucleus and accumulates in cytoplasmic inclusions.

Neuronal loss: The inclusions themselves may be toxic, and/or loss of nuclear TDP-43 function disrupts essential RNA processing.

Mechanisms of TDP-43 Toxicity

Multiple mechanisms contribute to neurodegeneration:

RNA processing disruption: Loss of nuclear TDP-43 impairs splicing of critical neuronal RNAs, including those encoding synaptic proteins and mitochondrial function genes.

Stress granule persistence: Pathological TDP-43 localizes to stress granules but fails to dissociate properly, causing prolonged translational repression.

Mitochondrial dysfunction: TDP-43 inclusions impair mitochondrial transport and function, reducing neuronal energy supply.

Axonal transport defects: TDP-43 pathology disrupts the microtubule-based transport system essential for synaptic maintenance.

Nucleocytoplasmic transport impairment: In C9orf72 cases, DPR proteins and TDP-43 aggregates disrupt nuclear pore integrity.

C9orf72 Expansion: From Gene to Disease

The Hexanucleotide Repeat Expansion

The C9orf72 gene contains a GGGGCC hexanucleotide repeat in its first intron. This region is normally polymorphic:

• Normal: 2-30 repeats
• Intermediate: 20-50 repeats (incomplete penetrance)
• Pathogenic: >30 repeats, typically hundreds to thousands

Three Pathogenic Mechanisms

The C9orf72 expansion causes neurodegeneration through three independent mechanisms:

1. Loss of Function (haploinsufficiency)
The expanded repeat causes reduced gene expression through:

• DNA hypermethylation at the repeat site
• Formation of DNA secondary structures that impede transcription
• Epigenetic silencing mechanisms

• Endosomal-lysosomal trafficking
• Autophagosome formation
• Rab GTPase regulation

2. RNA Toxicity (RNA Foci)
The expanded repeat RNA forms nuclear RNA foci that:

• Sequester RNA-binding proteins (TDP-43, hnRNP A1, Sam68)
• Disrupt normal RNA splicing
• Cause nucleolar stress

3. Dipeptide Repeat Protein Toxicity
Non-ATG translation of the repeat generates five DPR proteins:

• Poly-GA: Most abundant, forms inclusions, impairs proteasome
• Poly-GR/PR: Interact with stress granules, nucleocytoplasmic transport
• Poly-PA: Less characterized
• Poly-GP: Intermediate toxicity

Antisense Oligonucleotide Approaches

ASOs are single-stranded DNA oligonucleotides that:

• Bind to complementary target RNA
• Recruit RNase H to cleave the target
• Reduce levels of toxic RNA species

• ASOs targeting repeat RNA: Reduce RNA foci and DPR proteins
• ASOs targeting total C9orf72: Reduce both toxic RNA and reduce C9orf72 expression (controversial)

• Delivery to the CNS (intrathecal administration required)
• Need for continued dosing
• Variable patient response

Clinical Subtypes and Phenotypes

Behavioral Variant FTD-ALS

The most common overlapping presentation combines behavioral disinhibition with motor neuron disease:

Behavioral features:

• Early loss of social conduct
• Apathy and initiative loss
• Loss of empathy and emotional warmth
• Perseverative or compulsive behaviors
• Hyperorality and dietary changes

• Progressive limb weakness
• Bulbar dysfunction (dysarthria, dysphagia)
• Muscle atrophy and fasciculations
• Spasticity

Semantic Variant FTD-ALS

Characterized by progressive loss of word meaning and object knowledge combined with motor features:

Language features:

• Fluent speech with empty content
• Loss of object knowledge
• Surface dyslexia
• Preserved repetition and motor speech

• Often limb-onset ALS
• Less prominent frontobehavioral features

Progressive Muscular Atrophy (PMA)

A lower motor neuron-predominant syndrome that may evolve into ALS and FTD:

• Pure PMA has no upper motor neuron signs initially
• Approximately 30% develop ALS features
• Up to 50% develop cognitive/behavioral changes

Primary Lateral Sclerosis (PLS)

An upper motor neuron syndrome that may overlap with FTD:

• Pure PLS has isolated UMN signs
• 10-15% develop ALS features
• Cognitive changes common in PLS-FTD overlap

Diagnostic Criteria and Classification

ALS Diagnostic Criteria (Revised El Escorial)

Definite ALS: Clinical evidence of UMN and LMN signs in three regions Probable ALS: Clinical evidence of UMN and LMN signs in two regions, with UMN signs rostral to LMN signs Possible ALS: Clinical evidence of UMN and LMN signs in one region, or UMN signs alone in two regions Laboratory-supported probable ALS: EMG evidence of LMN signs in two regions with normal neuroimaging

FTD Diagnostic Criteria

Behavioral Variant FTD (Rascovsky criteria):

• Progressive behavioral decline
• Disinhibition or apathy or loss of empathy or perseveration/hyperorality
• Executive dysfunction or preserved memory
• Imaging support

• Nonfluent/agrammatic variant
• Semantic variant
• Logopenic variant (usually AD-related)

ALS-FTD Classification

Strong ALS-FTD: Both ALS and FTD criteria met at initial evaluation Weak ALS-FTD: ALS criteria met, then FTD features develop, or vice versa ALS with cognitive impairment: ALS with cognitive changes not meeting FTD criteria ALS with behavioral impairment: ALS with behavioral changes not meeting FTD criteria

Management: Beyond the Basics

Nutritional Support

Assessment:

• Weight monitoring (weekly)
• Dysphagia screening (EAT-10 questionnaire)
• Videofluoroscopic swallowing study if concerns

• Dietary modification (soft, pureed, thickened liquids)
• Caloric supplementation
• Gastrostomy tube placement before significant weight loss
• PEG tubes preferred over NG tubes (more secure, better toleration)

Respiratory Management

Monitoring:

• Forced vital capacity (FVC) monthly
• Sniff nasal pressure
• Overnight oximetry when FVC < 50% predicted

• Non-invasive ventilation (BiPAP) when:
• FVC < 50% predicted
• Morning headaches
• Sleep disturbance
• Daytime sleepiness
• Cough assist devices
• Secretion management (suctioning, anticholinergics)
• Mechanical ventilation (tracheostomy) for select patients

Symptom Control

Muscle cramps:

• Quinine (monitor for cardiac effects)
• Magnesium
• Physical therapy

• Baclofen (watch for sedation)
• Tizanidine
• Benzodiazepines
• Botulinum toxin for focal spasticity

• Dextromethorphan/quinidine (Nuedexta)

• Neuropathic pain agents (gabapentin, pregabalin)
• Opioids for severe pain (use judiciously)

• Glycopyrrolate
• Scopolamine patches
• Botulinum toxin to salivary glands

Pharmacological Management

Disease-modifying therapies:

• Riluzole 50mg twice daily
• Edaravone 60mg IV daily (28-day cycle)

• Coenzyme Q10 (mixed results)
• Lithium (conflicting data)
• Stem cell trials (various approaches)

End-of-Life Care

Advance care planning is essential:

• Discuss prognosis and preferences early
• Establish advance directives
• Plan for respiratory failure
• Palliative care involvement
• Hospice when appropriate

Biomarkers for Clinical Trials

Fluid Biomarkers

Neurofilament chains:

• NfL (neurofilament light chain): Elevated in CSF and blood, correlates with disease progression
• pNfH (phosphorylated neurofilament heavy chain): More specific to axonal injury
• Utility: Patient stratification, trial enrichment, pharmacodynamic markers

• C-terminal fragments in CSF
• Antibodies to TDP-43
• Utility: Diagnostic confirmation, target engagement

• C9orf72 repeat size
• Other ALS-FTD gene variants
• Utility: Genetic counseling, trial enrollment

Imaging Biomarkers

Structural MRI:

• Frontotemporal cortical thickness
• Corticospinal tract integrity (DTI metrics)
• Motor cortex volume

• FDG-PET hypometabolism patterns
• Connectivity changes in frontotemporal networks

• Fractional anisotropy in corticospinal tracts
• Mean diffusivity in frontal white matter

Electrophysiological Biomarkers

• Motor unit number estimation (MUNE): Tracks motor neuron loss
• CMAP amplitude: Correlates with disease progression
• Transcranial magnetic stimulation: Measures UMN integrity

Emerging Therapeutic Strategies

Small Molecule Approaches

Nucleocytoplasmic transport modulators:

• Importin inhibitors
• Nuclear pore-targeting compounds

• Compounds preventing granule formation
• Agents promoting granule dissolution

• Rapamycin and analogs
• Autophagy-enhancing small molecules

Immunotherapeutic Approaches

Anti-TDP-43 antibodies:

• Passive immunization approaches
• Targeting extracellular TDP-43

• Microglial activation modulators
• Anti-TNF approaches

Cell-Based Therapies

Stem cell approaches:

• Autologous mesenchymal stem cells
• Neural progenitor transplantation
• iPSC-derived motor neurons

• AAV delivery of therapeutic genes
• Non-viral delivery systems

Caregiver and Family Considerations

Caregiver Burden

ALS-FTD places extraordinary demands on caregivers:

• Physical assistance with activities of daily living
• Constant supervision due to behavioral disinhibition
• Communication challenges
• Emotional and psychological stress

• Respite care services
• Support groups (in-person and online)
• Caregiver education programs
• Mental health counseling

Family Genetic Counseling

For families with C9orf72 or other ALS-FTD mutations:

Testing considerations:

• Pre-symptomatic testing available for at-risk adults
• Requires genetic counseling
• Psychological support essential

• Prenatal diagnosis
• Preimplantation genetic testing (PGT)
• Gamete donation

Financial and Legal Planning

Insurance considerations:

• Disability insurance applications
• Long-term care planning
• Medicare/Medicaid eligibility

• Power of attorney
• Healthcare proxy
• Living wills
• Disability accommodations at work

References